Identification of Allergen-reactive Antibodies in the Blood of Pollen Allergic Patients

Status

Enrolling by invitation

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03727399

Enrollment

300

Registered

2018-11-01

Start date

2018-10-01

Completion date

2025-12-31

Last updated

2025-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pollen Allergy

Brief summary

The project examines the hypothesis that monoclonal allergen-neutralizing antibodies can be recombinantly produced from B lymphocytes isolated from pollen allergic patients. Patient samples suitable for antibody cloning are selected based on seroprofiling for the respective allergens. The study aims at isolating lymphocytes from patients with potential allergen-neutralizing IgG in serum and to clone antibodies from antibody gene sequences obtained from B cells of those patients.

Interventions

OTHERblood withdrawal

Blood withdrawal

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* History of allergic rhinitis, conjunctivitis or asthma due to sensitization to grass- or birch Allergens * Male or female patients older than 18 years * Written informed consent for providing blood and also to allow experimental manipulation

Exclusion criteria

* Age \< 18 years * Any corticosteroids within the last three days * Oral corticosteroid therapy within the last ten days * Parenteral depot corticosteroids within the last three months

Design outcomes

Primary

Measure	Time frame	Description
Antibody profiling	October 2018 - September 2021	Analysis and IgG profiling of specific antibodies binding major grass- and tree-pollen allergens in allergic patients.

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026